Healthcare ❯ Pharmaceuticals ❯ Drug Development

Clinical Research

Oncology Patient Care Phase 2 Trials Regulatory Affairs GLP-1 Medications Phase 3 Trials Patient Outcomes Fast Track Designation by FDA Eli Lilly FDA Regulations Novo Nordisk Regulatory Approval Oncology Treatments Trial Outcomes

MapLight’s Schizophrenia Candidate Posts Mixed Phase II Results as Shares Plummet

A twice-daily regimen hit key efficacy measures prompting MapLight to seek FDA input on a registrational trial.

AstraZeneca Beats Q2 Estimates and Reaffirms 2026 Guidance

GSK and Ionis Report Phase 3 Success for Hepatitis B Drug, Plan Q1 Filings

Eli Lilly to Acquire Verve Therapeutics for $1.3 Billion